Bristol-Myers Squibb to Buy Celgene in $74 Billion Pharma Deal

Bristol Myers Squibb is acquiring Celgene for $74 billion in a cash and stock deal. The acquisition, focused on cancer drugs like REVLIMID, comes amid market skepticism and follows an analyst call doubting large pharma deals. Investors are concerned about financing terms and regulatory approvals. Despite skepticism, this early-year mega deal suggests potential for more activity in the sector.

What was the total value of the deal between Bristol Myers Squibb and Celgene?

What was the main reason for Bristol Myers Squibb to acquire Celgene according to the text?

What concerns did investors have regarding the financing of the acquisition?

What regulatory challenges might Bristol Myers Squibb face in completing the acquisition?

What skepticism existed in the market regarding mega pharma deals at the time of the acquisition?